Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes
- Roswell Park Cancer Institute, United States
- University of Maryland, Baltimore County, United States
- University of Minnesota, United States
- University of Wisconsin-Milwaukee, United States
Abstract
Myeloid-derived suppressor cells (MDSC) contribute to an immunosuppressive network that drives cancer escape by disabling T cell adaptive immunity. The prevailing view is that MDSC-mediated immunosuppression is restricted to tissues where MDSC co-mingle with T cells. Here we show that splenic or, unexpectedly, blood-borne MDSC execute far-reaching immune suppression by reducing expression of the L-selectin lymph node (LN) homing receptor on naïve T and B cells. MDSC-induced L-selectin loss occurs through a contact-dependent, post-transcriptional mechanism that is independent of the major L-selectin sheddase, ADAM17, but results in significant elevation of circulating L-selectin in tumor-bearing mice. Even moderate deficits in L-selectin expression disrupt T cell trafficking to distant LN. Furthermore, T cells preconditioned by MDSC have diminished responses to subsequent antigen exposure, which in conjunction with reduced trafficking, severely diminishes antigen-driven expansion in widely-dispersed LN. These results establish novel mechanisms for MDSC-mediated immunosuppression that have unanticipated implications for systemic cancer immunity.
Article and author information
Author details
Funding
National Institutes of Health (CA79765)
- Sharon S Evans
UB Mark Diamond Research Fund
- Amy W Ku
Jennifer Linscott Tietgen Family Foundation
- Joseph J Skitzki
- Sharon S Evans
Breast Cancer Coalition of Rochester
- Scott I Abrams
- Sharon S Evans
NCI Cancer Center Support Grant (5P30 CA016056)
- Kieran O'Loughlin
- Hans Minderman
National Institutes of Health (1R50CA211108)
- Hans Minderman
National Institutes of Health (AI082039)
- Sharon S Evans
National Institutes of Health (T32 CA085183)
- Amy W Ku
National Institutes of Health (5T32 CA108456)
- Colin A Powers
National Institutes of Health (CA203348)
- Bruce Walcheck
National Institutes of Health (GM021248)
- Suzanne Ostrand-Rosenberg
National Institutes of Health (CA115880)
- Suzanne Ostrand-Rosenberg
National Institutes of Health (CA140622)
- Scott I Abrams
National Institutes of Health (CA172105)
- Scott I Abrams
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Ronald N Germain, National Institute of Allergy and Infectious Diseases, United States
Ethics
Animal experimentation: This study was performed in accordance with the recommendations in the NIH Guide for the Care and Use of Laboratory Animals. All of the animals were handled according to approved IACUC protocols at participating institutions (i.e., 859M and 1117M at Roswell Park Cancer Institute; SO01691417 at University of Maryland, Baltimore County; 15-16 #11 at University of Wisconsin, Milwaukee; and 1401-31272A at University of Minnesota). All surgery was performed under appropriate anesthesia and analgesia to minimize suffering and pain. The use of human PBMCs from anonymous, de-identified donors was classified as non-human subject research in accordance with federal regulations and thus not subjected to formal IRB review, but can be accessed through Roswell Park Clinical Research Services under the reference number BDR 069116.
Version history
- Received: April 29, 2016
- Accepted: December 7, 2016
- Accepted Manuscript published: December 8, 2016 (version 1)
- Version of Record published: December 29, 2016 (version 2)
Copyright
© 2016, Ku et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 3,138
- views
-
- 846
- downloads
-
- 68
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Tumor-induced MDSC act via remote control to inhibit L-selectin-dependent adaptive immunity in lymph nodes
eLife 5:e17375.
https://doi.org/10.7554/eLife.17375
Further reading
-
- Cancer Biology
- Cell Biology
Collective cell migration is fundamental for the development of organisms and in the adult, for tissue regeneration and in pathological conditions such as cancer. Migration as a coherent group requires the maintenance of cell-cell interactions, while contact inhibition of locomotion (CIL), a local repulsive force, can propel the group forward. Here we show that the cell-cell interaction molecule, N-cadherin, regulates both adhesion and repulsion processes during rat Schwann cell (SC) collective migration, which is required for peripheral nerve regeneration. However, distinct from its role in cell-cell adhesion, the repulsion process is independent of N-cadherin trans-homodimerisation and the associated adherens junction complex. Rather, the extracellular domain of N-cadherin is required to present the repulsive Slit2/Slit3 signal at the cell-surface. Inhibiting Slit2/Slit3 signalling inhibits CIL and subsequently collective Schwann cell migration, resulting in adherent, nonmigratory cell clusters. Moreover, analysis of ex vivo explants from mice following sciatic nerve injury showed that inhibition of Slit2 decreased Schwann cell collective migration and increased clustering of Schwann cells within the nerve bridge. These findings provide insight into how opposing signals can mediate collective cell migration and how CIL pathways are promising targets for inhibiting pathological cell migration.
-
- Cancer Biology
- Structural Biology and Molecular Biophysics
Abelson tyrosine kinase (Abl) is regulated by the arrangement of its regulatory core, consisting sequentially of the SH3, SH2, and kinase (KD) domains, where an assembled or disassembled core corresponds to low or high kinase activity, respectively. It was recently established that binding of type II ATP site inhibitors, such as imatinib, generates a force from the KD N-lobe onto the SH3 domain and in consequence disassembles the core. Here, we demonstrate that the C-terminal αI-helix exerts an additional force toward the SH2 domain, which correlates both with kinase activity and type II inhibitor-induced disassembly. The αI-helix mutation E528K, which is responsible for the ABL1 malformation syndrome, strongly activates Abl by breaking a salt bridge with the KD C-lobe and thereby increasing the force onto the SH2 domain. In contrast, the allosteric inhibitor asciminib strongly reduces Abl’s activity by fixating the αI-helix and reducing the force onto the SH2 domain. These observations are explained by a simple mechanical model of Abl activation involving forces from the KD N-lobe and the αI-helix onto the KD/SH2SH3 interface.
